Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

From the author

A. Bush
European Respiratory Journal 2007 29: 822; DOI: 10.1183/09031936.00003007
A. Bush
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

I would like thank A. Gammelgaard and H. Bisgaard for their interest in my Editorial 1. They welcome the European Union initiative and rightly highlight that more than just money and infrastructure is needed to achieve successful clinical trials in children. As they say, ethical issues are paramount, relatively poorly studied in children and should be the subject of further work. There is also a paucity of data about how best to make trials work on a day-to-day basis, as recently discussed 2. Indeed, the surest way of making a paediatric trial a failure is to take an adult protocol, change the word “adult” to “child” throughout with the word processor and attempt to make the trial work. It will not.

It is to be hoped that all these very important paediatric clinical trial issues, ethical, organisational and practical, can be developed through the Seventh Framework Programme (FP7) for research, so that the needs and expectations of Europe's most vulnerable community, small children, can be addressed, leading to truly evidence-based therapeutics.

    • © ERS Journals Ltd

    References

    1. ↵
      Bush A. Evidence-based medicines for children: important implications for new therapies at all ages. Eur Respir J 2006;28:1069–1072.
      OpenUrlFREE Full Text
    2. ↵
      Bush A. Clinical trials research in pediatrics. Strategies for effective collaboration between investigator sites and the pharmaceutical industry. Pediatr Drugs 2006;8:271–277.
      OpenUrlCrossRef
    PreviousNext
    Back to top
    View this article with LENS
    Vol 29 Issue 4 Table of Contents
    European Respiratory Journal: 29 (4)
    • Table of Contents
    • Index by author
    Email

    Thank you for your interest in spreading the word on European Respiratory Society .

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    From the author
    (Your Name) has sent you a message from European Respiratory Society
    (Your Name) thought you would like to see the European Respiratory Society web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Print
    Citation Tools
    From the author
    A. Bush
    European Respiratory Journal Apr 2007, 29 (4) 822; DOI: 10.1183/09031936.00003007

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero

    Share
    From the author
    A. Bush
    European Respiratory Journal Apr 2007, 29 (4) 822; DOI: 10.1183/09031936.00003007
    del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
    Full Text (PDF)

    Jump To

    • Article
      • References
    • Info & Metrics
    • PDF
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    More in this TOC Section

    • Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    • Optimised surveillance of bronchial dysplasia in risky population
    • Reply: Risk factors for disease progression in fibrotic hypersensitivity pneumonitis
    Show more Correspondence

    Related Articles

    Navigate

    • Home
    • Current issue
    • Archive

    About the ERJ

    • Journal information
    • Editorial board
    • Reviewers
    • Press
    • Permissions and reprints
    • Advertising

    The European Respiratory Society

    • Society home
    • myERS
    • Privacy policy
    • Accessibility

    ERS publications

    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS books online
    • ERS Bookshop

    Help

    • Feedback

    For authors

    • Instructions for authors
    • Publication ethics and malpractice
    • Submit a manuscript

    For readers

    • Alerts
    • Subjects
    • Podcasts
    • RSS

    Subscriptions

    • Accessing the ERS publications

    Contact us

    European Respiratory Society
    442 Glossop Road
    Sheffield S10 2PX
    United Kingdom
    Tel: +44 114 2672860
    Email: journals@ersnet.org

    ISSN

    Print ISSN:  0903-1936
    Online ISSN: 1399-3003

    Copyright © 2023 by the European Respiratory Society